Tema ETFs has been capitalizing on the danger appetite for bodyweight decline stocks.
It is powering the GLP-1, Weight problems & Cardiometabolic ETF (HRTS), which is up 26% due to the fact its inception last November.
The firm’s founder and CEO Maurits Pot thinks the winning body weight decline trade isn’t really centered on just hoopla.
“The organizations we keep track of and the organizations we devote in are hunting not just at a weight decline method, but also other approaches,” Pot informed CNBC’s “ETF Edge” on Monday. “We could see a globe in which the the vast majority of the world’s inhabitants requires a GLP-1, not just for bodyweight decline, but for other disorders.”
His top holdings include things like Mounjaro maker Eli Lilly and Ozempic and Wegovy maker Novo Nordisk. Eli Lilly is up 57% so much this calendar year, whilst Novo Nordisk is up 38%.
Moreover, Pot does not assume the price tag for GLP-1s to discourage new sufferers. He thinks they will occur down substantially in the following two to a few a long time.
“We could see drug pricing come down from $12,000 to maybe $6,000 a year, so maybe $500 a month,” claimed Pot, who points out insurance coverage coverage often helps make the treatment options far more reasonably priced to individuals.
